Patents by Inventor Takahisa Ogamino
Takahisa Ogamino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220162206Abstract: To provide a novel compound or a salt thereof or a solvate thereof, having a CSF-1R inhibitory activity and exhibiting antitumor effect. An azaindole derivative of formula (I): wherein A represents a C6-10 aryl ring, an aromatic heterocycle, or an unsaturated heterocycle, and A optionally has one substituent or more same or different substituents; and R represents a C1-3 alkyl group or a saturated heterocyclic group, or a salt thereof or a solvate thereof.Type: ApplicationFiled: March 30, 2020Publication date: May 26, 2022Applicant: KOWA COMPANY, LTD.Inventors: Gen WATANABE, Toshiharu MORIMOTO, Akira IWATA, Hirotaka SASAKI, Takahisa OGAMINO, Kosuke USUDA, Ayumu OKUDA, Hiroyuki ISHIWATA, Yuichiro TABUNOKI, Keigo NISHII
-
Patent number: 9242978Abstract: The present invention is to create a compound that selectively activates glucokinase in the liver, and in particular, to provide an agent for treating and preventing diabetes and impaired glucose tolerance, wherein the agent has a low hypoglycemia risk. A compound represented by the formula (1) as shown below, or a salt thereof, or a solvate of the compound or the salt: wherein, in the following formula (1), ring A represents a thiazolyl group, a pyridyl group, a pyrazyl group, or a pyrazolyl group; L represents —(CO)—, —(CS)—, or —SO2—; and R1 represents a C1-6 alkyl group, a hydroxy C1-6 alkyl group, a C1-6 alkoxy group, an amino group, a C1-6 alkylamino group, a hydroxyamino group, an N—C1-6 alkylcarbamoyl group, or a group represented by the formula (2) as shown below, wherein R3 represents a C1-6 alkyl group; and R2 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or a carboxyl group.Type: GrantFiled: September 25, 2013Date of Patent: January 26, 2016Assignee: Kowa Company, Ltd.Inventors: Takahisa Ogamino, Shin Tanikawa, Yoshiharu Miyake, Shinsuke Itoh, Yoshikazu Sawada
-
Publication number: 20150218151Abstract: The present invention is to create a compound that selectively activates glucokinase in the liver, and in particular, to provide an agent for treating and preventing diabetes and impaired glucose tolerance, wherein the agent has a low hypoglycemia risk. A compound represented by the formula (1) as shown below, or a salt thereof, or a solvate of the compound or the salt: [wherein, in the following formula (1), ring A represents a thiazolyl group, a pyridyl group, a pyrazyl group, or a pyrazolyl group; L represents —(CO)—, —(CS)—, or —SO2—; and R1 represents a C1-6 alkyl group, a hydroxy C1-6 alkyl group, a C1-6 alkoxy group, an amino group, a C1-6 alkylamino group, a hydroxyamino group, an N—C1-6 alkylcarbamoyl group, or a group represented by the formula (2) as shown below, wherein R3 represents a C1-6 alkyl group; and R2 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or a carboxyl group].Type: ApplicationFiled: September 25, 2013Publication date: August 6, 2015Inventors: Takahisa Ogamino, Shin Tanikawa, Yoshiharu Miyake, Shinsuke Itoh, Yoshikazu Sawada
-
Patent number: 8921576Abstract: The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic ?-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C1-6 alkyl group, a C6-10 aryl group, a cyano group, a C1-6 alkyl group optionally having a substituent, a C2-6 alkenyl group optionally having a substituent, etc.; R3 represents a hydrogen atom, a C1-6 alkyl group optionally having a substituent, etc.; and R4 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally having a substituent, etc.Type: GrantFiled: October 18, 2012Date of Patent: December 30, 2014Assignee: Kowa Company, Ltd.Inventors: Takahisa Ogamino, Yukiyoshi Yamazaki, Shin Tanikawa, Ayumu Okuda, Tomoaki Fukuda, Okihisa Tokuda, Yoshiharu Miyake, Shinsuke Itoh, Hiroyuki Ishiwata
-
Publication number: 20140309207Abstract: The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic ?-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C1-6 alkyl group, a C6-10 aryl group, a cyano group, a C1-6 alkyl group optionally having a substituent, a C2-6 alkenyl group optionally having a substituent, etc.; R3 represents a hydrogen atom, a C1-6 alkyl group optionally having a substituent, etc.; and R4 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally having a substituent, etc.Type: ApplicationFiled: October 18, 2012Publication date: October 16, 2014Inventors: Takahisa Ogamino, Yukiyoshi Yamazaki, Shin Tanikawa, Ayumu Okuda, Tomoaki Fukuda, Okihisa Tokuda, Yoshiharu Miyake, Shinsuke Itoh, Hiroyuki Ishiwata
-
Patent number: 8252781Abstract: [Object] It is to provide a novel compound useful for preventing and/or treating diseases that involves 11?-hydroxysteroid dehydrogenase 1 (in particular diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome). [Means to Solve the Object] A 1,2-diazetidin-3-one derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: October 28, 2009Date of Patent: August 28, 2012Assignee: Kowa Company, Ltd.Inventors: Hisashi Nakashima, Takaaki Araki, Takahisa Ogamino, Noriaki Gomi, Yasushi Kaneko, Kazutoyo Abe, Tadaaki Ohgiya
-
Patent number: 8236789Abstract: It is to provide a novel compound useful for preventing and/or treating diseases that involves 11?-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. It is an 1-adamantyl azetidin-2-one derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: August 28, 2009Date of Patent: August 7, 2012Assignee: Kowa Company, Ltd.Inventors: Hisashi Nakashima, Takahiro Mori, Ryoko Mori, legal representative, Takaaki Araki, Takahisa Ogamino, Kazutoyo Abe, Tadaaki Ohgiya
-
Publication number: 20100144694Abstract: [Object] It is to provide a novel compound useful for preventing and/or treating diseases that involves 11?-hydroxysteroid dehydrogenase 1 (in particular diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome). [Means to Solve the Object] A 1,2-diazetidin-3-one derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: October 28, 2009Publication date: June 10, 2010Applicant: KOWA COMPANY, LTD.Inventors: Hisashi Nakashima, Takaaki Araki, Takahisa Ogamino, Noriaki Gomi, Yasushi Kaneko, Kazutoyo Abe, Tadaaki Ohgiya
-
Publication number: 20100075943Abstract: It is to provide a novel compound useful for preventing and/or treating diseases that involves 11?-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. It is an 1-adamantyl azetidin-2-one derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: August 28, 2009Publication date: March 25, 2010Applicant: KOWA COMPANY, LTD.,Inventors: Hisashi Nakashima, Takahiro Mori, Takaaki Araki, Takahisa Ogamino, Kazutoyo Abe, Tadaaki Ohgiya, Ryoko Mori
-
Publication number: 20100022572Abstract: It is to provide a novel compound useful for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. A spiro compound represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: July 16, 2009Publication date: January 28, 2010Applicant: KOWA COMPANY, LTD.Inventors: Hisashi Nakashima, Takahisa Ogamino, Takaaki Araki, Noriaki Gomi, Yasushi Kaneko, Kazutoyo Abe, Tadaaki Ohgiya, Kimiyuki Shibuya
-
Publication number: 20080306102Abstract: A Spiro oxindole compound represented by formula (1) of the present invention or salt thereof, or their solvate shows a superior inhibitory effect of 11?-hydroxysteroid dehydrogenasel, and is useful as an agent for preventing or treating a disease that involves 11?-hydroxysteroid dehydrogenasel (in particular, diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome).Type: ApplicationFiled: May 16, 2008Publication date: December 11, 2008Applicant: KOWA CO., LTD.Inventors: Hisashi NAKASHIMA, Takaaki ARAKI, Takahisa OGAMINO, Yasushi KANEKO, Kazutoyo ABE, Kimiyuki SHIBUYA, Tadaaki OHGIYA